Aflibercept 8 mg two-year results from pivotal photon trial in diabetic macular edema presented at asrs

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements

REGN Ratings Summary

REGN Quant Ranking